Treatment of tripod fracture of zygomatic bone by N-2-butyl cyanoacrylate glue fixation, and its effects on the tissues.
The standard treatment of zygomatic bone fractures is fixation by microplates or miniplates and screws today. It is very difficult to place plates and screws into thin bones or small bone fragments especially in the facial bones and bones adjacent to important structures. Cyanoacrylate is used as a hemostatic agent, an embolic agent, in retinal tears, in corneal ulcers, in fixation of mandibular osteotomies and in craniofacial surgery. N-2-Butyl cyanoacrylate is a form of cyanoacrylate which is bioabsorbable and biocompatible. It is easily applied to the tissues. We aimed to determine the effect of N-2-butyl cyanoacrylate in the fixation of displaced zygomatic bone fractures. We examined the histotoxicity and the effects on healing and foreign body reaction of N-2-butyl cyanoacrylate. Eight New Zealand white rabbits underwent zygomatic osteotomies bilaterally. The fractures on left sides of the rabbits were determined as study site and right sides as control site. Knight and North classification of zygomatic bone fractures were used and group 4 fractures were made bilaterally. Open reduction of fractures was performed bilaterally and N-2-butyl cyanoacrylate was applied only on left sides. No fixation was made on right sides representing the control group. Postoperatively in the first, second, third and fourth weeks, two rabbits were sacrificed and the fracture sites were examined macroscopically and histopathologically. In the glued study group, fixation was obtained in all cases whereas in the control group, all the fractures were seen to be displaced. Tissue reaction was similar in the study and the control groups.
Dadaş
Burhan
B
Department of Otorhinolaryngology and Head and Neck Surgery, Sişli Etfal Teaching and Research Hospital, Fatih, Istanbul, Turkey. bdadas@yahoo.com
Alkan
Seyhan
S
Cifci
Memet
M
Başak
Tülay
T
D000818:Animals; D001843:Bone Cements / Q000494:pharmacology / Q000627:therapeutic use*; D004659:Enbucrilate / Q000494:pharmacology / Q000627:therapeutic use*; D005592:Fracture Fixation / Q000379:methods*; D005593:Fracture Fixation, Internal; D006097:Granulation Tissue / Q000187:drug effects*; D006490:Hemostatics / Q000494:pharmacology / Q000627:therapeutic use*; D011817:Rabbits; D015051:Zygomatic Fractures / Q000473:pathology / Q000628:therapy*
D001843:Bone Cements; D006490:Hemostatics; D004659:Enbucrilate